Gilead Sciences Files SC 13D/A Amendment for Galapagos NV
Ticker: GILD · Form: SC 13D/A · Filed: 2024-05-02T00:00:00.000Z
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
TL;DR
Gilead updated its Galapagos NV stake filing (SC 13D/A #3).
AI Summary
Gilead Sciences, Inc. filed an amendment (No. 3) to its Schedule 13D on April 30, 2024, regarding its holdings in Galapagos NV. The filing indicates a change in the beneficial ownership of Galapagos NV's ordinary shares by Gilead Sciences, Inc. The specific details of the change in ownership percentage or number of shares are not explicitly stated in this excerpt, but the amendment signifies an update to Gilead's reporting obligations.
Why It Matters
This filing is important as it signals a change in the significant ownership stake held by Gilead Sciences in Galapagos NV, potentially impacting the latter's stock performance and strategic direction.
Risk Assessment
Risk Level: medium — Changes in major shareholder filings can indicate shifts in strategy or potential future actions that could affect the company's stock.
Key Players & Entities
- Gilead Sciences, Inc. (company) — Filing entity and significant shareholder
- Galapagos NV (company) — Issuer of securities
- April 30, 2024 (date) — Date of event requiring filing
FAQ
What specific change in beneficial ownership triggered this amendment?
The provided excerpt does not specify the exact change in beneficial ownership percentage or number of shares, only that an amendment (No. 3) was filed on April 30, 2024.
What is the CUSIP number for Galapagos NV's ordinary shares?
The CUSIP number for Galapagos NV's ordinary shares is 36315X101.
What is the primary business of Galapagos NV according to the filing?
Galapagos NV is classified under Pharmaceutical Preparations (SIC code 2834).
What is the business address of Gilead Sciences, Inc. as listed in the filing?
Gilead Sciences, Inc.'s business address is 333 Lakeside Drive, Foster City, California, 94404.
What is the filing date of this Schedule 13D/A amendment?
The filing was made as of April 30, 2024, and the filing date is May 2, 2024.
From the Filing
0001193125-24-129680.txt : 20240502 0001193125-24-129680.hdr.sgml : 20240502 20240502212958 ACCESSION NUMBER: 0001193125-24-129680 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 GROUP MEMBERS: GILEAD THERAPEUTICS A1 UNLIMITED CO SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GALAPAGOS NV CENTRAL INDEX KEY: 0001421876 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88880 FILM NUMBER: 24910548 BUSINESS ADDRESS: STREET 1: GEN DE WITTELAAN L11 A3 CITY: 2800 MECHELEN STATE: C9 ZIP: 00000 BUSINESS PHONE: 3215342900 MAIL ADDRESS: STREET 1: GEN DE WITTELAAN L11 A3 CITY: 2800 MECHELEN STATE: C9 ZIP: 00000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13D/A 1 d829072dsc13da.htm SC 13D/A SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GALAPAGOS NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X101 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California, 94404 650-574-3000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 30, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  1   Names of Reporting Persons  Gilead Sciences, Inc.  2  Check the Appropriate Box if a Member of a Group (See Instructions)  (a) ☐  (b) ☐  3  SEC Use Only  4  Source of Funds (See Instructions)  AF  5  Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)  ☐  6  Citizenship or Place of Organization  Delaware Number of Shares Beneficially  Owned by Each Reporting Person With  7   Sole Voting Power  - 0 -  8  Shared Voting Power  20,981,010  9  Sole Dispositive Power  - 0 - 10  Shared Dispositive Power  20,981,010 11   Aggregate Amount Beneficially Owned by Each Reporting Person  20,981,010 12  Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)  ☐ 13  Percent of Class Represented by Amount in Row (11)  29.9%* 14  Type of Reporting Person ̳